Myelofibrosis Trials in London, United Kingdom
Conditions / Myelofibrosis / London, United Kingdom
Myelofibrosis is a medical condition with active clinical research programs worldwide.
24 total trials for this combination
Showing top 10 of 24 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | TERMINATED | PHASE3 |
| NCT02158858 | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | COMPLETED | PHASE1/PHASE2 |
| NCT04176198 | A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis | RECRUITING | — |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | TERMINATED | PHASE3 |
| NCT02426086 | Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor | COMPLETED | PHASE2 |
| NCT00235391 | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload | COMPLETED | PHASE3 |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD) | UNKNOWN | PHASE2 |
| NCT04603495 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06479135 | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | RECRUITING | PHASE3 |